News | September 20, 2024
Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
Stable profits, low leverage to keep credit profiles comfortable
Stable profits, low leverage to keep credit profiles comfortable
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
USFDA concludes inspection of Dr. Reddy's Laboratories R&D centre in Bachupally with zero observation
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Eugia Steriles receives EIR from USFDA for new injectable facility
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Subscribe To Our Newsletter & Stay Updated
